Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Read the full article on WikipediaSubfoveal choroidal neovascularisation (CNV) Clinical criteria: Treatment Phase: Initial treatment Treatment criteria: Must be treated by an ophthalmologist or by an accredited ophthalmology registrar in consultation with an ophthalmologist. The condition must be due to age-related macular degeneration (AMD), AND Patient must have persistent macular exudation, as determined clinically and/or by optical coherence tomography or fluorescein angiography, despite at least 6 months of PBS-subsidised treatment with: 1. Aflibercept and/or 2. Ranibizumab and/or 3. Faricimab, AND The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must not have previously received PBS-subsidised treatment with this drug for this condition. Authority approval for initial treatment of each eye must be sought. The first authority application for each eye must be made via the Online PBS Authorities System (real time assessment) or in writing via HPOS form upload or mail and must include: (1) Details (date, unique identifying number/code or provider number) of the optical coherence tomography or fluorescein angiogram report. If the application is submitted through HPOS form upload or mail, it must include: (a) details of the proposed prescription; and (b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). All reports must be documented in the patient's medical records.
Working under the parallel aged-care framework? Aged-care equivalent →